Development of a risk-stratification scoring system for predicting risk of breast cancer based on non-alcoholic fatty liver disease, non-alcoholic fatty pancreas disease, and uric acid
Many breast cancer patients have both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty pancreas disease (NAFPD). Consequently, we hypothesized that NAFPD and NAFLD were associated with breast cancer, and aimed to build a novel risk-stratification scoring system based on it. In this...
Main Authors: | Hong Chuntian, Yan Yonghao, Su Liyang, Chen Debo, Zhang Changqing |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2022-03-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2022-0462 |
Similar Items
-
Non-alcoholic fatty pancreas disease – practices for clinicians
by: Pinte Larisa, et al.
Published: (2019-09-01) -
Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis
by: Guntur Darmawan, et al.
Published: (2017-04-01) -
Evaluation of Serum Uric Acid as a Marker of Non-Alcoholic Fatty Liver Disease
by: Sadia Rehman, et al.
Published: (2020-04-01) -
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
by: Cheng-Wei Yu, et al.
Published: (2023-12-01) -
Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
by: Hak Soo Kim, et al.
Published: (2017-06-01)